In 2026, Co-Diagnostics entered an agreement with ReadyGo to assess whether its sample collection and preparation technologies are compatible with the Co-Dx PCR platform. The evaluation may streamline decentralized molecular testing, but remains preliminary and creates no obligation for development, supply, commercialization or another commercial arrangement.
Key Highlights
- ReadyGo has agreed to provide sampling materials for feasibility and compatibility studies involving Co-Diagnostics’ products.
- The technologies are designed to collect samples, stabilize nucleic acids and prepare biological material for molecular analysis.
- Co-Diagnostics’ Co-Dx PCR platform and associated tests remain subject to regulatory review and are not available for sale.
In August 2026, Co-Diagnostics, Inc. (NASDAQ: CODX) entered into an agreement with ReadyGo Diagnostics Ltd. to evaluate whether ReadyGo’s sample collection and preparation technologies are compatible with its Co-Dx PCR platform.
ReadyGo Materials Enter Feasibility Testing
Under the agreement, ReadyGo will provide certain sampling materials for feasibility studies and compatibility testing with Co-Diagnostics’ products. Co-Diagnostics believes those technologies may be complementary to its Co-Dx PCR platform, which is being developed around a compact instrument and proprietary test cups for real-time PCR testing outside traditional laboratory settings. The work reflects Co-Diagnostics’ stated objective of expanding access to molecular diagnostics in decentralized and point-of-care settings. Dwight Egan, chief executive officer, signed on behalf of Co-Diagnostics on Sep. 15, 2026.
FAQs
Q: What is Co-Diagnostics evaluating with ReadyGo?
A: Co-Diagnostics is assessing whether ReadyGo’s sample collection and preparation technologies are compatible with the Co-Dx PCR platform. The work involves feasibility and compatibility studies.
Q: Are Co-Diagnostics’ Co-Dx PCR products available for sale?
A: The Co-Dx PCR platform and associated tests are subject to review by the FDA and other applicable regulatory authorities. They are not currently available for sale.
Q: What happens after the ReadyGo feasibility studies?
A: The article does not specify what happens after the feasibility studies. It only states that ReadyGo will provide sampling materials for feasibility and compatibility testing with Co-Diagnostics’ products.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.